NeuroVasc Preclinical Services

Executive Summary

NeuroVasc Preclinical Services is a specialized contract research organization (CRO) providing preclinical efficacy pharmacology studies in central nervous system (CNS) and vascular disease models. Founded in 2015 and headquartered in San Diego, the company focuses on developing and utilizing animal models, particularly for stroke, to support drug development for pharmaceutical and biotechnology clients. Its expertise spans study planning, execution, analysis, and interpretation, offering high-level technical support to accelerate therapeutic pipelines. As a private, pre-clinical stage company, NeuroVasc fills a critical niche in the CRO market by combining deep scientific knowledge with a targeted service portfolio. With the growing demand for specialized preclinical services in neurology and cardiovascular indications, NeuroVasc is well-positioned to partner with drug developers seeking reliable, reproducible data for regulatory submissions. Its established track record and focus on complex disease models provide a competitive edge in a fragmented market, though scalability remains a key consideration.

Upcoming Catalysts (preview)

• Q4 2026Expansion of Stroke Model Portfolio (e.g., photothrombotic, tPA-compatible)70% success
• Q2 2027Strategic Partnership with a Mid-Size Biotech for CNS Drug Development50% success
• Q1 2027Publication of Validation Data for a Novel Vascular Dementia Model60% success